|
Obesity
|
0.200 |
Biomarker
|
disease |
MGD |
Mice without the regulator gene Rsc1A1 exhibit increased Na+-D-glucose cotransport in small intestine and develop obesity.
|
15601832 |
2005 |
|
Hepatorenal Syndrome
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
Hepatorenal syndrome type 1 (HRS-1), which is a specific type of AKI that occurs in the context of advanced cirrhosis and portal hypertension, is associated with particularly high mortality.
|
31723234 |
2020 |
|
Liver Cirrhosis
|
0.050 |
Biomarker
|
disease |
BEFREE |
Moreover, histological evidence of morphological abnormalities in the kidneys of patients with cirrhosis and renal dysfunction has prompted the functional nature of HRS-1 to be re-examined.
|
31723234 |
2020 |
|
Hepatorenal Syndrome
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
Hepatorenal syndrome type 1 (HRS-1), a form of acute kidney injury (AKI) in cirrhosis, has a median survival of days to weeks if untreated.
|
30887050 |
2019 |
|
Hepatorenal Syndrome
|
0.050 |
Biomarker
|
disease |
BEFREE |
Hepatorenal syndrome (HRS) has been defined as a purely "functional" type of renal failure that often occurs in patients with cirrhosis in the setting of marked abnormalities in arterial circulation, as well as overactivity of the endogenous vasoactive systems.<sup>4,5</sup> In 2007, the International Club of Ascites (ICA) classified HRS into types 1 and 2 (HRS-1 and HRS-2).<sup>5</sup> HRS-1 is characterised by a rapid deterioration of renal function that often occurs because of a precipitating event, while HRS-2 is a moderate and stable or slowly progressive renal dysfunction that often occurs without an obvious precipitant.
|
31302175 |
2019 |
|
Liver Cirrhosis
|
0.050 |
Biomarker
|
disease |
BEFREE |
A pilot observational study was conducted to determine the clinical utility of POCE-based examination of inferior vena cava diameter (IVCD) and collapsibility index (IVCCI) to assess intravascular volume status in patients with cirrhosis and AKI who had been deemed adequately volume-repleted and thereby assigned a clinical diagnosis of HRS-1.
|
31394538 |
2019 |
|
Liver Cirrhosis
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
Hepatorenal syndrome type 1 (HRS-1), a form of acute kidney injury (AKI) in cirrhosis, has a median survival of days to weeks if untreated.
|
30887050 |
2019 |
|
Liver Cirrhosis
|
0.050 |
Biomarker
|
disease |
BEFREE |
Hepatorenal syndrome (HRS) has been defined as a purely "functional" type of renal failure that often occurs in patients with cirrhosis in the setting of marked abnormalities in arterial circulation, as well as overactivity of the endogenous vasoactive systems.<sup>4,5</sup> In 2007, the International Club of Ascites (ICA) classified HRS into types 1 and 2 (HRS-1 and HRS-2).<sup>5</sup> HRS-1 is characterised by a rapid deterioration of renal function that often occurs because of a precipitating event, while HRS-2 is a moderate and stable or slowly progressive renal dysfunction that often occurs without an obvious precipitant.
|
31302175 |
2019 |
|
Liver Cirrhosis
|
0.050 |
Biomarker
|
disease |
BEFREE |
HRS is divided into HRS I, which is rapidly progressive and mostly seen in patients with decompensated liver cirrhosis, and HRS II, which progresses more slowly and is always accompanied by gross ascites.
|
30474439 |
2019 |
|
Hepatorenal Syndrome
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
Hepatorenal syndrome type 1 (HRS1) is a functional, rapidly progressive, potentially reversible form of acute kidney injury occurring in patients with cirrhosis.
|
28052382 |
2017 |
|
Hepatorenal Syndrome
|
0.050 |
Biomarker
|
disease |
BEFREE |
We evaluated the effect of SIRS on the response of hepatorenal syndrome type 1 (HRS-1) to terlipressin.
|
27464593 |
2017 |
|
Kidney Failure, Acute
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
However, new insights suggest that non-haemodynamic tubulo-toxic factors, such as endotoxins and bile acids, might mediate parenchymal renal injury in patients with cirrhosis, suggesting that concurrent mechanisms, including those traditionally associated with HRS-1 and non-traditional factors, might contribute to the development of AKI in patients with cirrhosis.
|
31723234 |
2020 |
|
Cirrhosis
|
0.040 |
Biomarker
|
disease |
BEFREE |
Moreover, histological evidence of morphological abnormalities in the kidneys of patients with cirrhosis and renal dysfunction has prompted the functional nature of HRS-1 to be re-examined.
|
31723234 |
2020 |
|
Kidney Failure, Acute
|
0.040 |
Biomarker
|
disease |
BEFREE |
A reduction in AKI stage, independent of HRS reversal, was sufficient to improve overall survival in patients with HRS-1.
|
30887050 |
2019 |
|
Kidney Failure, Acute
|
0.040 |
Biomarker
|
disease |
BEFREE |
A pilot observational study was conducted to determine the clinical utility of POCE-based examination of inferior vena cava diameter (IVCD) and collapsibility index (IVCCI) to assess intravascular volume status in patients with cirrhosis and AKI who had been deemed adequately volume-repleted and thereby assigned a clinical diagnosis of HRS-1.
|
31394538 |
2019 |
|
Kidney Failure, Acute
|
0.040 |
Biomarker
|
disease |
BEFREE |
In particular, the definitions and characterisation of acute kidney injury (AKI), acute kidney disease and chronic kidney disease have been introduced/refined.<sup>6</sup> Accordingly, a debate among hepatologists of the ICA led to a complete revision of the nomenclature and diagnosistic criteria for HRS-1, which was renamed HRS-AKI.<sup>7</sup> Additionally, over recent years, greater granularity has been gained regarding the pathogenesis of HRS; it is now increasingly recognised that it is not a purely "functional" entity with haemodynamic derangements, but that systemic inflammation, oxidative stress and bile salt-related tubular damage may contribute significantly to its development.
|
31302175 |
2019 |
|
Cirrhosis
|
0.040 |
Biomarker
|
disease |
BEFREE |
A pilot observational study was conducted to determine the clinical utility of POCE-based examination of inferior vena cava diameter (IVCD) and collapsibility index (IVCCI) to assess intravascular volume status in patients with cirrhosis and AKI who had been deemed adequately volume-repleted and thereby assigned a clinical diagnosis of HRS-1.
|
31394538 |
2019 |
|
Cirrhosis
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Hepatorenal syndrome type 1 (HRS-1), a form of acute kidney injury (AKI) in cirrhosis, has a median survival of days to weeks if untreated.
|
30887050 |
2019 |
|
Cirrhosis
|
0.040 |
Biomarker
|
disease |
BEFREE |
Hepatorenal syndrome (HRS) has been defined as a purely "functional" type of renal failure that often occurs in patients with cirrhosis in the setting of marked abnormalities in arterial circulation, as well as overactivity of the endogenous vasoactive systems.<sup>4,5</sup> In 2007, the International Club of Ascites (ICA) classified HRS into types 1 and 2 (HRS-1 and HRS-2).<sup>5</sup> HRS-1 is characterised by a rapid deterioration of renal function that often occurs because of a precipitating event, while HRS-2 is a moderate and stable or slowly progressive renal dysfunction that often occurs without an obvious precipitant.
|
31302175 |
2019 |
|
Dentatorubral-Pallidoluysian Atrophy
|
0.020 |
Biomarker
|
disease |
BEFREE |
HRS is divided into HRS I, which is rapidly progressive and mostly seen in patients with decompensated liver cirrhosis, and HRS II, which progresses more slowly and is always accompanied by gross ascites.
|
30474439 |
2019 |
|
Dentatorubral-Pallidoluysian Atrophy
|
0.020 |
Biomarker
|
disease |
BEFREE |
Because classification, nomenclature, diagnostic criteria and pathogenic theories have evolved over the years since the traditional classification of HRS-1 and HRS-2 was first described, it was considered that all these novel aspects be reviewed and summarised in a position paper.
|
31302175 |
2019 |
|
Retinoschisis, Juvenile, X-Linked
|
0.020 |
Biomarker
|
disease |
BEFREE |
These results support the use of rAAV2tYF-CB-hRS1 in clinical studies in patients with XLRS.
|
26390090 |
2015 |
|
Retinoschisis, Juvenile, X-Linked
|
0.020 |
Biomarker
|
disease |
BEFREE |
These results support the use of rAAV2tYF-CB-hRS1 in clinical studies in patients with XLRS.
|
26390091 |
2015 |
|
Portal Hypertension
|
0.010 |
Biomarker
|
disease |
BEFREE |
Hepatorenal syndrome type 1 (HRS-1), which is a specific type of AKI that occurs in the context of advanced cirrhosis and portal hypertension, is associated with particularly high mortality.
|
31723234 |
2020 |
|
Advanced cirrhosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Hepatorenal syndrome type 1 (HRS-1), which is a specific type of AKI that occurs in the context of advanced cirrhosis and portal hypertension, is associated with particularly high mortality.
|
31723234 |
2020 |